Loading...
Loading...
Application UK00909310897 · DO-NOT-DISPLAY
| Application Number | UK00909310897 |
| Status | DO-NOT-DISPLAY |
| Owner | Ipsen Pharma S.A.S |
| Filed | 2010-07-26 |
| Registered | 2011-02-10 |
| Renewal Due | 2020-07-26 |
| Type | Individual |
| Feature | Word |
| Attorney | See claim section below |
CAMPANULA Clinical Adaptive Multicenter Phase II triAl on carciNoid Underlying symptoms reLief with BIM 23A760 has a current status of DO-NOT-DISPLAY.
The specification below is taken directly from the filed record at the UK IPO for each Nice class this trademark is registered in.
Conducting of programmes for medical, pharmaceutical and scientific research, conducting of analyses and clinical research, scientifi, medical and pharmaceutical research.
'CAMPANULA Clinical Adaptive Multicenter Phase II triAl on carciNoid Underlying symptoms reLief with BIM 23A760' is a do-not-display trademark on the UK IPO register, owned by Ipsen Pharma S.A.S. The application (UK00909310897) was filed on 26 July 2010 and registered on 10 February 2011. The registration is set to expire on 26 July 2020.
This mark is recorded under Class 42 (scientific, IT & design services).
The trademark is represented by Hélène Bernard-Boyle IPSEN PHARMA S.A.S.
UK trademark UK00909310897 for the mark 'CAMPANULA Clinical Adaptive Multicenter Phase II triAl on carciNoid Underlying symptoms reLief with BIM 23A760' in Class 42 is recorded on the UK IPO register as owned by Ipsen Pharma S.A.S. This covers one specific UK trademark record only — the same brand name may be owned by different parties in other classes, other countries, or as separate registrations.
No — the UK IPO records the status of UK trademark UK00909310897 for the mark 'CAMPANULA Clinical Adaptive Multicenter Phase II triAl on carciNoid Underlying symptoms reLief with BIM 23A760' as do-not-display.
UK trademark UK00909310897 for the mark 'CAMPANULA Clinical Adaptive Multicenter Phase II triAl on carciNoid Underlying symptoms reLief with BIM 23A760' is registered in Class 42 (scientific, IT & design services). The filed specification reads: Class 42: Conducting of programmes for medical, pharmaceutical and scientific research, conducting of analyses and clinical research, scientifi, medical and pharmaceutical research.
UK trademark UK00909310897 for the mark 'CAMPANULA Clinical Adaptive Multicenter Phase II triAl on carciNoid Underlying symptoms reLief with BIM 23A760' was filed at the UK IPO on 26 July 2010 and registered on 10 February 2011.
UK trademark UK00909310897 for the mark 'CAMPANULA Clinical Adaptive Multicenter Phase II triAl on carciNoid Underlying symptoms reLief with BIM 23A760' is currently recorded as valid until 26 July 2020, at which point it will need to be renewed with the UK IPO to remain in force.
Hélène Bernard-Boyle IPSEN PHARMA S.A.S is listed as the attorney / representative of record for UK trademark UK00909310897 for the mark 'CAMPANULA Clinical Adaptive Multicenter Phase II triAl on carciNoid Underlying symptoms reLief with BIM 23A760' on the UK IPO register.
This trademark has an attorney of record listed on the UK register. The firm has not yet claimed its listing on Trademark Dashboard.
UK trademark data is supplied by the Intellectual Property Office under the Open Government Licence v3.0.
The “About This Trademark” summary and FAQ above are AI-generated from the register data shown on this page. They are factual summaries only — always verify details against the official register before making legal decisions.